The United Nations Children’s Fund (UNICEF) announced yesterday (Aug. 16) that Glaxosmith Klein (GSK), the British drugmaker, had been involved in the treatment of the disease. Selected for the world’s first malaria vaccine contract to protect millions of children from dying from the disease
The contract is worth more than $170 million. This will lead to 18 million doses of the RTS,S vaccine available over the next three years, saving thousands of lives each year.
Xinhua news agency reported that Children under the age of five remain at risk of developing malaria, with nearly 500,000 boys and girls in Africa alone in 2020 dying from the disease. Or accounted for the number of deaths at the rate per person ever.
UNICEF’s Director of Supply Ethleva Cadilli said the announcement was a clear message to malaria vaccine developers. To continue to develop a vaccine like this
Ms Cadilli said: “We hope this is just the beginning. Continuous innovation is needed to increase the number of vaccines available. and strengthening the vaccine market,” he added, “This is a huge step forward in our collective effort to save children’s lives. and reduce the burden of malaria as part of a broader malaria prevention and control program.”
By InfoQuest News Agency (17 Aug 65)
Tags: GSK, UNICEF, malaria, UNICEF, malaria vaccine, England, Ethleva Cadilli, Glaxo Smith Klein